Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days
  1. Condition:   Neuroendocrine Tumors
    Intervention:   Radiation: MIBG-I131
    Sponsor:   AC Camargo Cancer Center
    Recruiting
  2. Condition:   Neuroendocrine Tumors
    Intervention:   Drug: 64Cu-SARTATE
    Sponsor:   Clarity Pharmaceuticals Ltd
    Recruiting
  3. Condition:   Neuroendocrine Tumors
    Intervention:   Diagnostic Test: 68Ga-DOTA-TATE
    Sponsors:   Centre de recherche du Centre hospitalier universitaire de Sherbrooke;   Université de Sherbrooke
    Recruiting
  4. Conditions:   EGFR-Mutated Non-Small-Cell Lung Carcinoma;   Small Cell/Neuroendocrine
    Interventions:   Drug: Olaparib;   Drug: Durvalumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  5. Condition:   Neuroendocrine Carcinoma
    Interventions:   Drug: FOLFOXIRI Protocol;   Drug: Cisplatin injection
    Sponsors:   Centre Hospitalier Universitaire Dijon;   National Cancer Institute, France
    Recruiting
  6. Conditions:   Metastatic Large Cell Neuroendocrine Carcinoma;   Metastatic Neuroendocrine Carcinoma;   Metastatic Neuroendocrine Neoplasm;   Metastatic Small Cell Neuroendocrine Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  7. Conditions:   Neuroendocrine Tumors;   Carcinoid Syndrome;   Diarrhea
    Interventions:   Drug: Telotristat ethyl;   Drug: Peptide Receptor Radionuclide Therapy;   Other: Placebo
    Sponsors:   Pashtoon Kasi, MD, MS;   TerSera Therapeutics LLC
    Recruiting
  8. Conditions:   Prostate Cancer Metastatic;   Neuroendocrine Tumors
    Interventions:   Drug: Pembrolizumab;   Drug: Lenvatinib
    Sponsors:   Ulka Vaishampayan;   Merck Sharp & Dohme Corp.;   University of Michigan
    Not yet recruiting
  9. Conditions:   Locally Advanced Digestive System Neuroendocrine Carcinoma;   Locally Advanced Pancreatic Neuroendocrine Carcinoma;   Metastatic Digestive System Neuroendocrine Carcinoma;   Metastatic Pancreatic Neuroendocrine Carcinoma;   Refractory Digestive System Neuroendocrine Carcinoma;   Refractory Pancreatic Neuroendocrine Carcinoma;   Unresectable Digestive System Neuroendocrine Carcinoma;   Unresectable Pancreatic Neuroendocrine Carcinoma
    Interventions:   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Liposomal Irinotecan;   Procedure: Quality-of-Life Assessment
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Ipsen
    Recruiting
  10. Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Locally Advanced Pancreatic Neuroendocrine Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Tumor G1;   Metastatic Pancreatic Neuroendocrine Tumor;   Metastatic Thymic Neuroendocrine Neoplasm;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Serotonin-Producing Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  11. Condition:   Neuroendocrine Tumors
    Interventions:   Drug: 177Lu-edotreotide PRRT;   Drug: Everolimus;   Other: Amino-Acid Solution
    Sponsors:   ITM Solucin GmbH;   ABX CRO;   PSI CRO AG
    Recruiting
  12. Condition:   Carcinoma, Neuroendocrine
    Intervention:   Drug: [177]Lu-DOTA-TATE
    Sponsor:   AHS Cancer Control Alberta
    Recruiting
  13. Conditions:   Lung Small Cell Carcinoma;   Neuroendocrine Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
    Interventions:   Biological: Dostarlimab;   Drug: Niraparib
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting
  14. Conditions:   Locally Advanced Well Differentiated Neuroendocrine Neoplasm;   Metastatic Well Differentiated Neuroendocrine Neoplasm
    Interventions:   Drug: Placebo Administration;   Other: Questionnaire Administration;   Drug: Telotristat Ethyl
    Sponsor:   M.D. Anderson Cancer Center
    Not yet recruiting
  15. Conditions:   Neuroendocrine Tumours;   Neuroendocrine Tumour of the Lung;   Small Intestinal NET
    Intervention:   Drug: Surufatinib
    Sponsor:   Hutchison Medipharma Limited
    Not yet recruiting
  16. Conditions:   Neuroendocrine Tumor;   Liver Metastases;   Neuroendocrine Gastroenteropancreatic Tumour
    Interventions:   Procedure: Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection;   Procedure: Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection;   Drug: LUTATHERA® by intra-arterial hepatic (IAH) injection;   Procedure: Scan
    Sponsors:   University Hospital, Bordeaux;   Advanced Accelerator Applications
    Not yet recruiting
  17. Conditions:   Gastro-enteropancreatic Neuroendocrine Tumor;   Neuroendocrine Tumors
    Interventions:   Drug: Lutathera;   Drug: Azedra
    Sponsors:   David Bushnell;   National Institutes of Health (NIH);   National Cancer Institute (NCI);   Progenics Pharmaceuticals, Inc.
    Not yet recruiting
  18. Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  19. Conditions:   SCLC;   Small Cell Cancer;   Advanced Solid Tumor;   High Grade Neuroendocrine Cancers
    Interventions:   Drug: Lurbinectedin;   Drug: Berzosertib
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  20. Conditions:   Advanced Adrenal Gland Pheochromocytoma;   Advanced Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Paraganglioma;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma
    Interventions:   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  21. Condition:   Gastro-enteropancreatic Neuroendocrine Tumor
    Interventions:   Drug: Lutathera;   Drug: long-acting octreotide;   Drug: high dose long-acting octreotide
    Sponsor:   Advanced Accelerator Applications
    Recruiting
  22. Conditions:   Gastric Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Sarcoma;   Mesothelioma;   Neuroendocrine Tumors;   Squamous Cell Cancer;   Merkel Cell Carcinoma;   Mismatch Repair Deficiency;   Microsatellite Instability
    Interventions:   Biological: Tumor Infiltrating Lymphocytes (TIL);   Drug: Fludarabine + Cyclophosphamide combination
    Sponsor:   Udai Kammula
    Recruiting
  23. Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Breast Metaplastic Carcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Solid Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  24. Conditions:   Pheochromocytoma;   Paraganglioma;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Ga-68-DOTATATE;   Drug: F-18-FDG;   Drug: Amino Acid solution
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  25. Conditions:   Surgery;   Analgesia
    Interventions:   Drug: Liposomal bupivacaine;   Other: Thoracic epidural analgesia (bupivacaine)
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Pacira Pharmaceuticals, Inc
    Not yet recruiting
  26. Condition:   Tumors
    Intervention:   Drug: surufatinib
    Sponsor:   Hutchison Medipharma Limited
    Recruiting
  27. Conditions:   Bladder Small Cell Neuroendocrine Carcinoma;   Extensive Stage Lung Small Cell Carcinoma;   Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Limited Stage Lung Small Cell Carcinoma;   Platinum-Resistant Lung Small Cell Carcinoma;   Platinum-Sensitive Lung Small Cell Carcinoma;   Prostate Small Cell Neuroendocrine Carcinoma;   Recurrent Lung Small Cell Carcinoma
    Interventions:   Drug: Berzosertib;   Drug: Topotecan Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  28. Conditions:   Bladder Adenocarcinoma;   Bladder Clear Cell Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Neuroendocrine Carcinoma;   Bladder Small Cell Neuroendocrine Carcinoma;   Bladder Squamous Cell Carcinoma;   Bladder Urachal Adenocarcinoma;   Chromophobe Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Urethral Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor;   Urethral Clear Cell Adenocarcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  29. Condition:   Covid19
    Interventions:   Drug: Inhaled Aviptadil;   Drug: Placebo
    Sponsors:   Centurion Pharma;   Klinar CRO
    Recruiting
  30. Condition:   NASH - Nonalcoholic Steatohepatitis
    Interventions:   Drug: Estradiol patch;   Drug: Placebo
    Sponsor:   Massachusetts General Hospital
    Not yet recruiting
  31. Conditions:   Appendix Carcinoma;   Colon Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Malignant Digestive System Neoplasm;   Pancreatic Carcinoma;   Rectal Carcinoma;   Small Intestinal Carcinoma;   Anal Carcinoma;   Digestive System Carcinoma;   Digestive System Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor
    Interventions:   Procedure: Acupuncture Therapy;   Procedure: Acupressure Therapy;   Procedure: Oral Cryotherapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   The Safeway Foundation
    Recruiting
  32. Conditions:   Metastatic Solid Tumor;   Colorectal Cancer;   Neuroendocrine Tumors;   Small Cell Lung Cancer;   Gastric Cancer;   Soft Tissue Sarcoma
    Interventions:   Drug: Surufatinib and Tislelizumab _ Part 1;   Drug: Surufatinib and Tislelizumab _ Part 2
    Sponsors:   Hutchison Medipharma Limited;   BeiGene
    Recruiting
  33. Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting
  34. Conditions:   Motor Function;   Cognitive Function;   Contrast Media
    Interventions:   Procedure: Motor Tests;   Procedure: Cognitive Tests;   Procedure: Unenhanced-MRI of the brain;   Procedure: Gadolinium Measurements;   Drug: Gadoxetate disodium;   Drug: Gadobenate dimeglumine;   Drug: Gadodiamide;   Drug: Gadoterate meglumine;   Drug: Gadobutrol;   Drug: Gadoteridol
    Sponsors:   Guerbet;   Bayer AG (Sponsor);   Bracco (Sponsor);   GEHC (Sponsor)
    Recruiting
  35. Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting
  36. Condition:   Breast Cancer
    Interventions:   Drug: alpelisib;   Drug: fulvestrant;   Drug: letrozole;   Drug: Goserelin;   Drug: Leuprolide
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  37. Conditions:   Locally Advanced Thyroid Gland Carcinoma;   Malignant Thyroid Gland Neoplasm;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Thyroid Gland Anaplastic Carcinoma;   Thyroid Gland Medullary Carcinoma;   Thyroid Gland Papillary Carcinoma;   Thyroid Gland Squamous Cell Carcinoma
    Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Selpercatinib;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting
  38. Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8;   Unclassified Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  39. Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  40. Conditions:   Adenoid Cystic Skin Carcinoma;   Adnexal Carcinoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Apocrine Carcinoma;   Cylindrocarcinoma;   Digital Papillary Adenocarcinoma;   Endocrine Mucin-Producing Sweat Gland Carcinoma;   Extramammary Paget Disease;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Papillary Adenocarcinoma;   Porocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Merkel Cell Carcinoma;   Refractory Mycosis Fungoides;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Skin Squamous Cell Carcinoma;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamoid Eccrine Ductal Carcinoma;   Squamous Cell Carcinoma of Unknown Primary;   Sweat Gland Carcinoma;   Trichilemmal Carcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  41. Condition:   Vestibular Schwannoma
    Interventions:   Drug: NiMODipine Injectable Solution;   Other: Placebo
    Sponsor:   Medical University of Vienna
    Not yet recruiting
  42. Conditions:   Viral Pneumonia;   Serotonin Syndrome;   Platelet Dysfunction
    Intervention:   Drug: Cyproheptadine Hydrochloride 4 MG
    Sponsors:   Ciusss de L'Est de l'Île de Montréal;   Covid-19 Early Treatment Fund
    Not yet recruiting